Medical Devices

Quanta System on the Peaks of the Urological Laser World Once Again: Quanta Magneto Technology™

Retrieved on: 
Friday, April 5, 2024
Health, Medical Devices, Surgery, General Health, Research, Science, Biotechnology, Quanta, Sorbonne University, Lithotripsy, Magneto, Holmium, History, Prostate, EAU, Surgeon, Safety, Cancer, Multimedia, Computer data storage

View the full release here: https://www.businesswire.com/news/home/20240404169544/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240404169544/en/
    Cyber Ho Magneto with Quanta Magneto Technology™ (Photo: Business Wire)
    On the way to its 40th anniversary Quanta System remains steadfast in its mission: innovate to improve the lives of people around the world; with an unwavering belief that progress is always possible.
  • The global leader in laser technologies continually collaborates with medical professionals, working side by side with doctors to advance healthcare.
  • It is this commitment that drives the latest groundbreaking addition to the Cyber Ho family: Cyber Ho Magneto.
  • Cyber Ho Magneto, in fact, is the first laser system that tamed the peak power of holmium, turning it into a much longer pulse duration providing the superior dusting of a Thulium Fiber Laser.

Spineology® Appoints new Member to Leadership Team; Spine Veteran Emory Rooney joins as Executive Vice President of Sales

Retrieved on: 
Thursday, April 4, 2024
Medical Devices, Health, Hospitals, Surgery, Physical Therapy, Biotechnology, Freedom, University, Growth, Medicine, Learning, Central Florida, Inc., Area, Patient, Medical device, IDE, Surgeon, ATEC, Spine, Pain

Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales.

Key Points: 
  • Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales.
  • Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years.
  • “The addition of Emory adds even further conviction about our clear opportunity for growth at Spineology,” said Brian Snider, Chief Executive Officer at Spineology.
  • Prior to joining Spineology, Mr. Rooney spent nearly six years with Alphatec Spine (Nasdaq: ATEC), where he served as the Vice President of Sales, East.

Signifier Medical Technologies’ eXciteOSA Now Covered by Medicaid in South Carolina: Reaching a Wider Patient Population with Daytime Sleep Apnea Therapy

Retrieved on: 
Thursday, April 4, 2024
Medical Devices, Insurance, Health Technology, Professional Services, Public Policy, Government, Health Insurance, Managed Care, State, Local, General Health, Health, Health care, Obstructive sleep apnea, Partnership, Patient, Human services, Overalls, Quality of life, Sleep apnea, Medicaid, Pharmaceutical industry

Signifier Medical Technologies Limited (“Signifier”), a leader in medical technology for sleep-disordered breathing, is thrilled to announce that eXciteOSA therapy is now covered by South Carolina’s Healthy Connections Medicaid program .

Key Points: 
  • Signifier Medical Technologies Limited (“Signifier”), a leader in medical technology for sleep-disordered breathing, is thrilled to announce that eXciteOSA therapy is now covered by South Carolina’s Healthy Connections Medicaid program .
  • This significant milestone further broadens access to eXciteOSA’s revolutionary daytime therapy for obstructive sleep apnea, ensuring that more individuals can benefit from this innovative and effective treatment.
  • "We are thrilled that eXciteOSA is now covered by Medicaid in South Carolina," states Akhil Tripathi, Director and Co-founder of Signifier.
  • Signifier extends its gratitude to the South Carolina Department of Health and Human Services for their partnership in expanding access to obstructive sleep apnea therapy for Medicaid beneficiaries.

STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024

Retrieved on: 
Thursday, April 4, 2024
Optical, Health, Surgery, Medical Devices, ICL, U.S. FDA, Growth, Presbyopia, Near-sightedness, Sale, EVO, Bank statement, Investment, FDA, Astigmatism

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million with U.S. ICL sales expected to be $5 million for the quarter.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million with U.S. ICL sales expected to be $5 million for the quarter.
  • “STAAR is off to a solid start in 2024 as illustrated by our preliminary first quarter results including a record quarter in the U.S.,” said Tom Frinzi, President and CEO of STAAR Surgical.
  • ICL sales were up approximately 20% sequentially to $5 million in the first quarter, which reflects early signs of our increased market focus.
  • The Company expects to report complete first quarter financial results and discuss its fiscal 2024 outlook during its quarterly earnings call on or about May 8, 2024.

Paragon 28 Announces CFO Transition, Provides Preliminary Unaudited Net Revenue for First Quarter 2024, and Reaffirms Net Revenue Guidance for Fiscal Year 2024

Retrieved on: 
Thursday, April 4, 2024
Surgery, Health, Medical Devices, Paragon, Growth, CFO, Webcast, Knowledge, Foot, Ankle, FNA, Interim management, Interim, Audit committee

The Company concurrently announced the appointment of Kristina Wright as Interim CFO, effective April 3, 2024.

Key Points: 
  • The Company concurrently announced the appointment of Kristina Wright as Interim CFO, effective April 3, 2024.
  • Thomas Schnettler, lead independent director for Paragon 28, will assume the role of interim Chair of the Audit Committee.
  • The Company reaffirms its prior 2024 net revenue guidance and continues to expect 2024 net revenue to be $249 million to $259 million, representing 15.1% and 19.7% reported growth compared to 2023.
  • Paragon 28 will report first quarter 2024 financial results after market close on Wednesday, May 8, 2024.

Veristat Joins the Alliance for Regenerative Medicine (ARM) to Help Address Critical Issues Impacting the Advanced Therapy Sector

Retrieved on: 
Wednesday, April 3, 2024
Stem Cells, Consulting, Pharmaceutical, Oncology, Professional Services, Biometrics, General Health, Medical Devices, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, Health, Research, MED, Member, Regenerative medicine, Patient, ARM, Pharmaceutical industry

The announcement falls the week before members of Veristat’s Executive team are attending ARM’s Cell & Gene Meeting on the Med (#MeetingOnTheMed) being held in Rome, Italy.

Key Points: 
  • The announcement falls the week before members of Veristat’s Executive team are attending ARM’s Cell & Gene Meeting on the Med (#MeetingOnTheMed) being held in Rome, Italy.
  • “Advanced therapies have proven themselves as holding numerous benefits for patients struggling with rare and ultra-rare diseases, areas that account for 35% of our work,” stated Patrick Flanagan, Chief Executive Officer of Veristat.
  • “Veristat is proud to have supported the development of the first gene therapy approved in Europe.
  • ARM’s mission centers on enabling the development of advanced therapies and the modernization of healthcare systems so that patients benefit from durable, potentially curative treatments.

Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024

Retrieved on: 
Wednesday, April 3, 2024
Women, Other Manufacturing, Consumer Electronics, Seniors, Technology, Diabetes, Men, General Health, Family, Manufacturing, Consumer, Teens, Parenting, Medical Devices, Children, Baby, Maternity, Health Technology, LGBTQ+, Other Technology, Health, Wearables, Mobile Technology, Corporation, Eastern Time Zone

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2024 on May 9, 2024 after the close of the financial markets.

Key Points: 
  • Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2024 on May 9, 2024 after the close of the financial markets.
  • In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).
  • The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com , “Events and Presentations,” and will be archived for future replay.
  • You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2109 for international callers, passcode is 5904836.

Asahi Kasei Medical and AW Technologies enter exclusive distribution agreement for TrachFlush in Japan

Retrieved on: 
Wednesday, April 3, 2024
Medical Devices, Health, CE marking, Ventilator-associated pneumonia, Partnership, Patient, AW, Sale, QOL, Workload, Multimedia, ICU, Phlegm, FDA, Marketing

AW Technologies and Asahi Kasei Medical, a core operating company of the Asahi Kasei Group, have entered into an exclusive distribution agreement in Japan for AW Technologies’ TrachFlush™ device.

Key Points: 
  • AW Technologies and Asahi Kasei Medical, a core operating company of the Asahi Kasei Group, have entered into an exclusive distribution agreement in Japan for AW Technologies’ TrachFlush™ device.
  • AW Technologies is currently in the process of medical device registration of the TrachFlush in Japan, with market launch targeted in fiscal 2024.
  • Adam Hansen, CEO of AW Technologies, commented, "We are very pleased and excited to announce our partnership with Asahi Kasei Medical.
  • This partnership is very important for AW Technologies, and Asahi Kasei Medical will play a very important role in our expansion of TrachFlush globally.

Recent Research Supports Sedation-Free TNE for Effective Management of GI Disorders Utilizing the EvoEndo System

Retrieved on: 
Wednesday, April 3, 2024
Health, Medical Devices, Hospitals, Health Technology, Other Health, General Health, Biotechnology, Safety, Anesthesia, TNE, Evaluation, Patient, Pediatrics, Efficacy, Abstract, Male, Workflow, EGD, Eosinophilic esophagitis, Endoscopy, Esophagogastroduodenoscopy, Nursing

Recently published scientific abstracts and peer-reviewed papers support the efficacy and demand for gastroenterology programs to offer Sedation-Free Transnasal Endoscopy (TNE) utilizing the EvoEndo System as an alternative to traditional TNE.

Key Points: 
  • Recently published scientific abstracts and peer-reviewed papers support the efficacy and demand for gastroenterology programs to offer Sedation-Free Transnasal Endoscopy (TNE) utilizing the EvoEndo System as an alternative to traditional TNE.
  • Findings suggest a valuable opportunity to optimize the patient experience, minimize risks associated with anesthesia, and improve diagnostic outcomes.
  • There were no adverse events, suggesting promising potential for TNE as a diagnostic tool in assessing esophageal disorders.
  • These studies highlight the advantages of offering unsedated TNE and the viability of broader applications in pediatric endoscopy.

Harris County Public Health Partners with Lightbeam Health Solutions to Improve Maternal Health Outcomes for 15K Community Members

Retrieved on: 
Wednesday, April 3, 2024
Medical Devices, Hospitals, Health, Nursing, Managed Care, Mother, Conference, Partnership, Patient, Conditional sentence, Child, CHC, SDOH, JD, Woman, Medicaid, Maternal health, Multimedia, Medicare, ACCESS, RPM, Person

This project aims to provide real-time support for maternal health, SDOH, and gaps in care in Harris County, Texas, spanning 15,000 community members.

Key Points: 
  • This project aims to provide real-time support for maternal health, SDOH, and gaps in care in Harris County, Texas, spanning 15,000 community members.
  • “Lightbeam enthusiastically embraces the opportunity to support the HCPH team in improving healthcare quality and accessibility for its most vulnerable maternal health community members,” says Blake Marggraff, CEO of Lightbeam Health Solutions.
  • The Lightbeam RPM Maternal Health and Post-Partum Depression programs have seen high engagement rates (75-77%), helped to improve breastfeeding outcomes, and have generated more than 2,300 productive, actionable alerts.
  • We’re thrilled to partner with HCPH and in alliance with its mission to bring equitable, scalable care to its community members.”
    “ACCESS Harris County is excited to begin this partnership with Lightbeam Health Solutions to improve healthcare access and quality for the county's maternal health population.